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Abstract
Tumor growth and metastasis is a complex pathophysiological process comprising of various interactions between tumor cells and the host(I-3). A significant approach in understanding tumor invasion and metastasis is by identifying the genes involved in tumor growth and suppression, and investigating their molecular mechanisms and eventually in their role as therapeutic agent, if any. Maspin is a tumor suppressor gene related to the serine protease inhibitor (serpin) family (4) . It is expressed in normal prostate epithelial cells, but is down regulated as normal prostate cells progress from a pre-neoplastic to an invasive state. This down regulation is mediated in vitro at the transcriptional level through cis-acting elements and trans-acting factors in the maspin promoter(5)'. Further, recombinant maspin is shown to inhibit prostate tumor-induced growth and neovascularization in a xenograft nude mouse model and inhibit tumor invasion and motility of prostatic cell lines in vitro (6) .
This proposal aims to investigate the tumor suppressor function of maspin in vivo, and thereby as a novel molecular target in the treatment of prostate cancers. The specific aims for this two-year proposal are: Specific Aim 1. To investigate the effect of maspin in a syngeneic xenograft mouse model of prostate cancer. Specific Aim 2. To establish a transgenic mouse overexpressing maspin in the prostate to study the role of gain of function of maspin in prostate cancer.
Objective 1: To generate a bitransgenic mice expressing maspin in the prostate in the context of an inducible system Objective 2: To cross the bigenic maspin mice with TRAMP mice to investigate the tumor suppressor function of maspin in vivo.
In the last two years, both specific aims were initiated. We have tested the effect of maspin in a syngeneic xenograft mouse model of prostate cancer. Maspin cDNA was introduced into TRAMP prostate tumor C2N cells. Parental C2N cells and maspin stable cells were injected subcutaneously into C57BL/6 mice. We show that tumor growth was blocked in maspin expressing tumors in vivo. Further analyses show that maspin inhibits angiogenesis and induces tumor cell apoptosis. These results have been summarized for the preparation of manuscript. With regard to the second specific aim, we have generated floxed beta-geo-maspin transgenic mice. These mice have also been crossed with PBARR2-cre mice to generate bitransgenic mice. Unfortunately, two transgenic mouse lines we generated all expressed very low level of maspin transgene after Cre recombianse deletion. As with all animal experiments, this problem is hard to predict. We are trying alternative approaches to overcome the problem at the moment.
Body Materials and methods

Animals
Syngeneic C57BL/6 mice (for implantation of TRAMP tumor cells) were purchased from Harlan, Inc. All animals were maintained within the PI's animal facility at Baylor. TRAMP cell lines were obtained from Dr. Norm Greenberg at Baylor College of Medicine.
Antibodies
Polyclonal anti-maspin antibody was made by Zymed, Inc. as a custom service. All secondary antibodies were purchased from Zymed, Inc.
Northern and Western analysis
RNAs and proteins were isolated from cells, prostate tissues. Total RNAs were isolated using Gibco/BRL Trizol regent. For northern blot, roughly 20 ug RNA will be loaded each lane. For Western blot analysis, protein extracts were prepared by lysing the cells in non-ionic detergent-containing buffers. Total 100 ug protein extract will be loaded for electrophoresis.
Immunohistochemical analysis
Prostate tissues were removed from male mice and dissected. Tissues were fixed in 10% neutral formalin buffer and embedded in paraffin and sectioned at 5 [tm. For maspin immunostaining, tissues were boiled in citrate buffer (Zymed, Inc.) for ten minutes for antigen retrival. The antibody was produced in rabbit against a fifteen amino acid peptide located in the reactive site loop of maspin, a region designated as AbS4A. The antibody was purified using an AbS4A sulfo-linked affinity column (Sulfolink kit, Pierce, IL). The sections were stained with the affinity purified maspin antibody at a dilution of 1:400, followed by a secondary goat antirabbit antibody staining, and the color was developed by Zymed's AEC (3-Amino-9-Ethylcarbazole) chromogen kit. For specific peptide blocking, a concentration of 10 nM of AbS4A peptide was preincubated with antibody for thirty minutes at room temperature. For proliferating cell nuclear antigen (PCNA) staining, a PCNA staining kit was purchased from Zymed (Zymed, Inc., CA) and slides were stained following the instruction of the kit.
Results and Discussion
Task 1. Examination of maspin as a tumor suppressor in prostate.
We have overexpressed maspin in TRAMP (TRansgenic Animal Model of Prostate cancer) prostate tumor cells by retrovirus infection (7) . Retroviral stable transfectants were selected. We used a C2N mouse prostate tumor cell line that was initially isolated from TRAMP tumors in Dr.
Norman Greenburg's { §Pk".t~&tcompared the tumor cell expressing C2N-Maspin tumor cells had significant increase of apoptosis than that of C2N control cells (Fig.2) . In addition, we carried out experiments to determine whether the secreted maspin from C2N-maspin tumors could inhibit tumor growth by affecting angiogenesis. Using the collected conditional medium we showed that endothelial cell migration was significantly inhibited (Fig.3) . Thus, the reason for the tumor inhibition in maspin clones in vivo may be due to the combined effect of increased tumor cell apoptosis and inhibition of angiogenesis. recognized by bacteriophage P GCre expression of cre recombinase. gal). We have breed our floxed betageo-maspin transgenic mice with Dr. Wang's ARR2-cre to generate bitransgenic mice. Unfortunately, two parental transgenic mouse lines we generated all expressed very low level of maspin transgene after Cre recombianse deletion. Although the B-geo signal is present we believe that chick-b-actin promoter that was used to direct the beta-geo/maspin expression is too weak in prostate. We are taking two approaches to overcome the difficult in making the tissue specific maspin transgenic mice. The first is to inject more old construct to generate more transgenic lines so that we have the possibility to select one high maspin expression line after crossing with Arr2-cre. The other possibility is to change the chicken actin promoter into a elongation factor promoter. This promoter is capable of driving gene expression in prostate tissue (personal communication with Dr. Alexander, BCM). We are now in the process of generating more transgenic lines for the screening and will proceed with the second approach if our first approach fails. I would like to emphasize that we have done the experiments as proposed in the statement of work in the last two years, although the result was not what we expected. Despite the fact that this fellowship has already expired, we remain hopeful to continue to build a transgenic mouse model for prostate study. Thus, we will continue the experiments to study the effect of maspin overexpression on prostate development and tumorigenesis.
Key research accomplishments x
Clones of prostate tumor cells without (C2N) and with (C2NM) maspin expression grew equally well in liquid and semisolid culture media, but only the C2N cells developed into palpable tumors in C57BL/6 mice. Condition medium from C2N-maspin cells were collected for western blot analysis with maspin antibody. Our data showed that C2N-maspin medium contained detectable level of maspin protein. Using the collected conditional medium we showed that endothelial cell migration was significantly inhibited. These data indicate that maspin prevents tumor angiogenesis in mice. We are currently preparing a manuscript for this study. Transgenic mice of B-geo/maspin have been established and have been crossed with ARR2-Cre transgenic mice. However, due to some technical problems, the level of maspin remains too low. We are currently building more mouse lines to select for better transgenic strain.
Reportable outcome Products 1. Establishing a syngeneic tumor implantation model using C2N TRAMP tumor cells 2. Animal models developed -Transgenic mice were developed to express maspin and the beta-geo marker.
-Bitransgenic mice were developed to express the ROSA26 reporter and thereby demonstrate expression of cre recombinase by ARR2-cre mice.
We are currently focusing to study the effect of maspin overexpression on prostate development and the transgenic mice will be crossed with prostate oncogenic mice to examine the role of maspin tumorigenesis.
Conclusion
Two tasks proposed in the grant were initiated in the first year of proposal. Key reagents have been obtained and transgenic mice have been developed. Continuation of the tasks in the next few years will help us understand the role of maspin in prostate development and tumor metastasis, and hopefully leading to the development of new therapies for the treatment of prostate cancer.
